Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2012
At a glance
- Drugs Amrubicin (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 05 Jun 2009 New trial record.